NASDAQ:ANIP

ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis

ANI Pharmaceuticals logo
$71.39 +1.40 (+2.00%)
As of 11:45 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About ANI Pharmaceuticals Stock (NASDAQ:ANIP)

Advanced

Key Stats

Today's Range
$69.85
▼
$71.27
50-Day Range
$67.41
▼
$78.85
52-Week Range
$67.14
▼
$87.76
Volume
45,863 shs
Average Volume
390,279 shs
Market Capitalization
$1.62 billion
P/E Ratio
14.18
Dividend Yield
N/A
Price Target
$100.00
Consensus Rating
Hold

Company Overview

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. Its portfolio includes products in areas such as rare disease, specialty care and established brands, alongside a range of generic drugs.

The company’s rare-disease portfolio includes Purified Cortrophin Gel, a prescription medicine used to treat certain inflammatory and other conditions. ANI also produces and markets complex and specialty generics, which can require more involved development or manufacturing than conventional generic drugs.

Founded in 1996, ANI serves the U.S. market and has expanded its capabilities through acquisitions, including its 2021 acquisition of Novitium Pharma. The company is led by President and Chief Executive Officer Nikhil Lalwani.

AI Generated. May Contain Errors.

ANI Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
66th Percentile Overall Score

ANIP MarketRank™: 
3.286834064035 of 5 stars

ANI Pharmaceuticals scored higher than 66% of companies evaluated by MarketBeat, and ranked 171st out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ANI Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 3 buy ratings, 4 hold ratings, and no sell ratings.

  • Upside Potential

    ANI Pharmaceuticals has a consensus price target of $100.00, representing about 40.6% upside from its current price of $71.14.

  • Amount of Analyst Coverage

    ANI Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

  • Read more about ANI Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for ANI Pharmaceuticals are expected to grow by 2.75% in the coming year, from $7.99 to $8.21 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ANI Pharmaceuticals is 14.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.88.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ANI Pharmaceuticals is 14.14, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.93.

  • Price to Earnings Growth Ratio

    ANI Pharmaceuticals has a PEG Ratio of 2.22. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    ANI Pharmaceuticals has a P/B Ratio of 2.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    16.98% of the float of ANI Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    ANI Pharmaceuticals has a short interest ratio ("days to cover") of 11.88, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in ANI Pharmaceuticals has recently increased by 3.21%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    ANI Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    ANI Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    ANI Pharmaceuticals has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for ANI Pharmaceuticals this week, compared to 6 articles on an average week.
  • Search Interest

    Only 2 people have searched for ANIP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added ANI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ANI Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,975,156.00 in company stock.

  • Percentage Held by Insiders

    8.10% of the stock of ANI Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    76.05% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about ANI Pharmaceuticals' insider trading history.
Receive ANIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ANIP Stock News Headlines

ANI Pharmaceuticals Earnings Call Highlights Growth
Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
See More Headlines

ANIP Stock Analysis - Frequently Asked Questions

ANI Pharmaceuticals' stock was trading at $78.94 at the beginning of the year. Since then, ANIP stock has decreased by 9.9% and is now trading at $71.14.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) posted its earnings results on Thursday, November, 5th. The specialty pharmaceutical company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.18 by $0.52. The business's revenue was up 27.6% compared to the same quarter last year.
Read the conference call transcript
.

ANI Pharmaceuticals' top institutional investors include Soleus Capital Management L.P. (4.29%), State Street Corp (4.14%), Aberdeen Group plc (1.46%) and William Blair Investment Management LLC (1.07%). Insiders that own company stock include Muthusamy Shanmugam, Nikhil Lalwani, Stephen P Carey, Chad Gassert, James G Marken, Christopher Mutz, Ori Gutwerg, Meredith Cook, Krista Davis, Thomas Haughey, Patrick D Walsh, Thomas Andrew Rowland, Jeanne Thoma, Renee P Tannenbaum, Antonio R Pera and Matthew J Leonard.
View institutional ownership trends
.

Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ANI Pharmaceuticals investors own include NVIDIA (NVDA), Bristol Myers Squibb (BMY), Micron Technology (MU), Broadcom (AVGO), Gilead Sciences (GILD), Alibaba Group (BABA) and Salesforce (CRM).

Company Calendar

Last Earnings
11/05/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ANIP
Previous Symbol
NASDAQ:BPAX
CIK
1023024
Employees
970
Year Founded
1996

Price Target and Rating

High Price Target
$121.00
Low Price Target
$85.00
Potential Upside/Downside
+40.7%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
$5.02
Trailing P/E Ratio
14.13
Forward P/E Ratio
8.66
P/E Growth
2.22
Net Income
$78.34 million
Net Margins
11.22%
Pretax Margin
15.16%
Return on Equity
28.34%
Return on Assets
11.18%

Debt

Debt-to-Equity Ratio
0.92
Current Ratio
2.75
Quick Ratio
2.33

Sales & Book Value

Annual Sales
$883.37 million
Price / Sales
1.83
Cash Flow
$9.96 per share
Price / Cash Flow
7.14
Book Value
$28.03 per share
Price / Book
2.54

Miscellaneous

Outstanding Shares
22,730,000
Free Float
20,889,000
Market Cap
$1.62 billion
Optionable
Optionable
Beta
0.45

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:ANIP) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners